home.aspx

 
.

FIBRO-INFLAMMATORY DISEASE SEES RELIEF IN IL-11 MAB DEVELOPMENT

SHARESHARESHARE
Biologic drugs have dominated the biopharmaceutical market in recent years and show no signs of slowing. While there is no shortage of therapeutic targets for drug developers designing monoclonal antibodies (mAB), validating those targets for clinical efficacy in various disease models is growing increasingly difficult. Since IL-11 was recently identified as an essential cytokine for inflammation and fibrosis, Enleofen and Aldevron developed monoclonal anti-IL-11 and anti-IL11RA antibodies for the treatment of non-alcoholic steatohepatitis (NASH) and other conditions.